Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Would you offer adjuvant endocrine therapy to a male with ER+ DCIS?
Related Questions
What are your top takeaways in Breast Cancer from ASCO 2024?
What neoadjuvant chemotherapy regimen would you choose for a triple positive (ER+/PR+/HER2+) cT2N1 G3 breast cancer for an elderly patient (80 y/o)?
What is your preferred sequencing of adjuvant chemotherapy and PMRT for node + breast cancer?
Is there a role for adjuvant pembrolizumab/capecitabine in a patient with TNBC who receives neoadjuvant AC-T with residual disease found at time of surgery?
Would history of breast cancer deter you from using ospemifene for severe vaginal dryness/dyspareunia?
Do you hold endocrine therapy during adjuvant breast radiotherapy?
In light of the NSABP B-51 data presented at SABCS, will you defer RNI in all patients with negative nodes after chemotherapy?
Would a low genomic Mammaprint score deter you from offering adjuvant chemotherapy to a premenopausal woman with pT3N0 breast cancer?
How would you treat a young premenopausal female with triple negative inflammatory breast cancer who progressed on carboplatin/paclitaxel/pembrolizumab (KEYNOTE 522), but didn't receive anthracycline portion and has a positive BRCA2 mutation?
Do you routinely check hormone levels to confirm postmenopausal status before adding aromatase inhibitors to lupron in premenopausal women with early breast cancer?